Wang et al. [82] investigated three well-defined polymorphisms (rs156699, rs157077, and rs7085725) within the GSTO2-2 gene to determine their potential to predict OS among 228 HCC patients undergoing a transarterial chemoembolization (TACE) treatment. The gene discussed is GSTO2; the disease is hepatocellular carcinoma.